Ultragenyx Pharmaceutical Inc.

RARE

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Baker Bros. Advisors RTW Investments Rock Springs Capital

Catalysts

No catalysts tracked.

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 2,772,692Value: $63.8M

## Signal Note: Baker Bros. Initiates Large Position in Ultragenyx (RARE) **Note: The reported position value of ~$63.8B appears to be a data error — 2.77M shares at recent prices (~$40-50/share) would value the stake at roughly $110-140M, which is the plausible figure and still represents a significant conviction bet.** Baker Bros. building a new ~2.8M share position in Ultragenyx is a high-conviction signal given their concentrated, specialist approach and strong track record in rare disease. RARE's near-term catalyst path centers on **setrusumab** (anti-sclerostin antibody for osteogenesis imperfecta), with a PDUFA decision expected in H2 2025 following a priority review, plus ongoing commercial ramp of **Daiichi Sankyo-partnered C

RTW InvestmentsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ALKS3 funds ARGX3 funds NGNE3 funds CNTA3 funds INSM3 funds ACAD3 funds KYMR3 funds MDGL

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: RTW Investments Initiates $69M Position in Ultragenyx (RARE) RTW's $69M entry into Ultragenyx likely signals confidence in the company's late-stage pipeline, particularly around gotictinib (FGFR3 inhibitor) for achondroplasia, which has shown clinical efficacy and faces a competitive but underserved market (estimated $1B+ opportunity). Key near-term catalysts include potential FDA decisions on achondroplasia indication and data readouts in other ultra-rare genetic disorders where Ultragenyx maintains clinical programs. The position timing suggests conviction ahead of anticipated clinical/regulatory milestones in 2024-2025.